Medical oncology and Precision Medicine

All Items

• Understanding quality of life in Danish women with metastatic breast cancer undergoing multiple treatments

  Helle Pappot, Annasofie Jørgensen, Anna Hincheli Bjørum, Christina Bøgh Jakobsen, Camilla Uhre Jørgensen, Beverley Lim Høeg, Pernille Bidstrup, Ann Knop, Line Bentsen

  292-302

• Fine needle aspiration cytology including the analysis of human papilloma virus (HPV) DNA enhances the diagnostic workup of solitary cystic neck lesions in a population with a high incidence of HPV positive oropharyngeal cancer

  Evelina Jörtsö, Linda Marklund, Martin Harper Hysek, Anders Näsman, Lalle Hammarstedt-Nordenvall, Mathias von Beckerath, Tina Dalianis, Rusana Bark

  276-283

• Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy

  Rutger H. Stoffers, Anne G.H. Niezink, Olga Chouvalova, Jan F. Ubbels, Marleen Woltman-van Iersel, T. Jeroen N. Hiltermann, Lucie B.M. Hijmering-Kappelle, Gea Douma, Sander M. de Hosson, John W.G. van Putten, Friso T. Zandberg, Lisanne V. van Dijk, Johannes A. Langendijk, Robin Wijsman

  267-275

• Infantile undifferentiated sarcomas: a diagnostic and therapeutic challenge – two case reports and literature review

  Aleksandra Stanio, Jakub Czarny, Sandra Rutkowska, Katarzyna Adamczewska-Wawrzynowicz, Łukasz Młynarczyk, Agnieszka Stróżyk, Katarzyna Jończyk-Potoczna, Alicja Bartkowska-Śniatkowska, Jacek Wachowiak, Katarzyna Derwich, Olga Zając-Spychała

  241-246

• Health-related Quality of Life and hospital costs of Finnish melanoma patients participating in the second Multicenter Selective Lymphadenectomy Trial (MSLT-II)

  Pia J. Heino, Jukka Pappinen, John F. Thompson, Micaela Hernberg, Tiina A. Jahkola, Mark B. Faries

  247-256

• Determining the effect of frailty on survival in advanced ovarian cancer: study protocol for a prospective multicentre national cohort study (FOLERO)

  Daniel Hunde, Niklas Ekerstad, Mihaela Asp, Päivi Kannisto, Madelene Wedin, Charlotte Palmqvist, Pernilla Dahm-Kähler, Yvonne Brandberg, Mirna Abraham-Nordling, Kristina Åhlund, Vilhelm Mörlin, Nina Groes-Kofoed, Sahar Salehi

  208-213

• Relapse detection in the Danish surveillance program of patients with clinical stage I seminoma: a nationwide study

  Niklas B. Lindahl, Jakob Lauritsen, Thomas Wagner, Gedske Daugaard, Mikkel Bandak

  191-199

• Real-world treatment patterns and survival outcomes in men with metastatic castration-resistant prostate cancer in Finland: a national, population-based cohort study

  Antti Rannikko, Olivia Hölsä, Trude Ågesen, Mattias Ekman, Riikka Mattila

  173-178

• Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer – real-world single-centre data

  Bogdana Patachi, Kristian H. Jensen, Anita Gothelf, Mogens Bernsdorf, Jeppe Friborg, Claus A. Kristensen

  143-146

• Knowledge and understanding of information after taking decision to participate or not in a randomized trial of surgery vs radiotherapy among patients with locally advanced prostate cancer – an observational study

  Yvonne Brandberg, Olof Akre, Mia Bergenmar

  167-172

• Organ preservation, for rectal cancer: general overview of the latest data from phase III randomized trials

  Syrine Ben Dhia, Damien Chauviere, Diana Mitrea, Renaud Schiappa, Tanguy Pace Loscos , Emmanuel Chamorey , David Baron

  120-128

• Coasting related to taxane-induced peripheral neuropathy in patients with breast cancer: a systematic review

  Freja L. Kruse, Margrethe B. Bille, Maria E. Lendorf, Susan Vaabengaard, Steffen Birk

  78-86

• Distinct patterns of osteoradionecrosis after photon-based radiotherapy and carbon ion radiotherapy for unresectable adenoid cystic carcinoma of the head and neck: case series from two institutions

  Eivind Storaas, Marta D. Switlyk, Sigrun Dahl, Cecilie D. Amdal , Åse Bratland, Thuy-Tien M. Huynh, Hanne A. Eide, Barbara Vischioni, Ester Orlandi, Einar Dale

  63-68

• Long-term survival of participants in the PASART-1 and PASART-2 trials of neo-adjuvant pazopanib and radiotherapy in soft tissue sarcoma

  Bauke H.G. van Riet, Milan van Meekeren, Marta Fiocco, Aisha Miah, Ilse de Pree, Lisette M. Wiltink, Astrid Scholten, Lotte Heimans, Judith V.M.G. Bovée, Hans Gelderblom, Neeltje Steeghs, Rick L. Haas

  69-77

• Maintenance treatment with trofosfamide in patients with advanced soft tissue sarcoma – a retrospective single-centre analysis

  Anton Burkhard-Meier, Vera Valerie Rechenauer, Luc M. Berclaz, Vindi Jurinovic, Markus Albertsmeier, Hans Roland Dürr, Sinan E. Güler, Michael Hoberger, Alexander Klein, Thomas Knösel, Wolfgang G. Kunz, Nina-Sophie Schmidt-Hegemann, Michael von Bergwelt-Baildon, Lars H. Lindner, Dorit Di Gioia

  56-62

• The clinical utility of circulating human papillomavirus across squamous cell carcinomas

  Karen-Lise G. Spindler, Anne V. Jakobsen, Jesper G. Eriksen, Lars Fokdal, Marianne Nordsmark, Lise B. J. Thorsen, Karen L. Wind, Anna C. Lefevre, Jens Overgaard

  1-12

• Real-world data on utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer: impact on surgical complications and oncological efficacy

  Hege S. Haugnes, Hakon Kjaeve, Eivind Bjerkaas, Ragnhild Hellesnes, Line Hjelle, Magnus Larsen

  13-21

• Imaging-based evaluation of cervical muscle mass and 6-month survival in males with hypopharyngeal carcinoma

  Jouni Laurén, Harri Keski-Säntti, Antti Mäkitie, Otso Arponen

  950-957

• Clinico-pathological characteristics and treatment outcome in non-small cell lung cancer in Greenland 2015–2020 – a comparison with the cohort from 2004 to 2010

  Dorte S. Nørøxe, Simone Frandsen, Malene M. Clausen, Thomas I. Hansen, Uka W. Geisler, Alice J. Petersen, Seppo W. Langer

  958-964

• From trials to practice: Immune checkpoint inhibitor therapy for melanoma patients in Norway

  Denise Reis Costa, Anna K. Winge-Main, Anna Skog, Kaitlyn M. Tsuruda, Trude Eid Robsahm, Bettina Kulle Andreassen

  965-973

• ESHO 2–85. Hyperthermia as an adjuvant to radiation therapy in the treatment of advanced neck nodes: A randomized multicenter study by the European Society for Hyperthermic Oncology

  Jens Overgaard, Olav Dahl, Giorgio Arcangeli

  943-949

• Denosumab combined with radiotherapy as an alternative to surgery for advanced metastatic bone lesions and pathologic fractures: a retrospective case study of 38 patients

  Mehdy Farhang, Martin Isaksson, Johan Wänman, Richard Löfvenberg, Sead Crnalic

  932-938

• Adherence to adjuvant endocrine therapy after breast cancer in Sweden – a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences

  Anna De Jong, Anna Von Wachenfeldt, Lennarth Nyström, Anne Andersson

  901-908

• NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial

  Jean-Matthieu L'Orphelin, Ugo Lancien , Jean-Michel Nguyen , Francisco J.S. Coronilla, Soraya Saiagh , Julie Cassecuel , Lise Boussemart, Anne Dompmartin , Brigitte Dréno

  867-877

• The impact of age on clinicopathological features and treatment results in patients with localised prostate cancer receiving definitive radiotherapy

  Cem Onal, Ozan Cem Guler, Aysenur Elmali, Birhan Demirhan, Melek Yavuz

  858-866

• A dosimetric and robustness analysis of proton arc therapy with early energy layer and spot assignment for lung cancer versus conventional intensity modulated proton therapy

  Macarena S. Chocan, Sophie Wuyckens, Damien Dasnoy, Dario Di Perri, Elena Borderias Villarruel, Erik Engwall, John A. Lee, Ana M. Barragan-Montero, Edmond Sterpin

  805-815

• Stereotactic body radiation therapy on abdominal-pelvic lymph node oligometastases: a systematic review on toxicity

  Lucy A. van Werkhoven, Eugenio Cammareri, Mischa S. Hoogeman, Remi A. Nout, Maaike T.W. Milder, Joost J.M.E. Nuyttens

  822-832

• Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas

  Lisa Millgård Sagberg, Øyvind Salvesen, Asgeir Store Jakola, Erik Thurin, Eddie de Dios, Noah L.A. Nawabi, John L. Kilgallon, Joshua D. Bernstock, Vasileios K. Kavouridis, Timothy R. Smith, Ole Solheim

  798-804

• Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study

  Mari Lahelma, Heini Rauhamaa, Riikka-Leena Leskelä, Outi Isomeri, Juhana Idänpään-Heikkilä, Sari Käkelä, Nichola Roebuck, Barbara Mascialino, Sakari Hietanen, Mikko Loukovaara, Annika Auranen

  763-771

• Real-life treatment patterns and time to next treatment among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland Study

  Mari Lahelma, Heini Rauhamaa, Outi Isomeri, Juhana Idänpään-Heikkilä, Sari Käkelä, Nichola Roebuck, Barbara Mascialino, Sakari Hietanen, Mikko Loukovaara, Annika Auranen

  772-782

• Classic Kaposi sarcoma: Diagnostics, treatment modalities, and genetic implications – A review of the literature

  Ron Batash, Alberto Crimí, Riad Kassem, Murad Asali, Ishay Ostfeld, Carlo Biz, Pietro Ruggieri, Moshe Schaffer

  783-790

• Assessment of radiation pneumonitis and predictive factors in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

  Kerstin Gunnarsson, Louise Mövik, Niclas Pettersson, Anna Bäck, Jan Nyman, Andreas Hallqvist

  791-797

• Intensity-modulated proton radiotherapy spares musculoskeletal structures in regional nodal irradiation for breast cancer: a dosimetric comparison

  Jessica F. Burlile, Satomi Shiraishi, Heather J. Gunn, Jennifer L. Bradt, Haley M. Kroeplin, Karen G. Lang, Jenna K. Cimmiyotti, Nicolas Depauw, Connie Y. Chang, Kevin M. Brom, Cassandra L. Sonnicksen, Anhmai Vu, Rachel B. Jimenez, Kimberly S. Corbin

  755-762
• 

  Home self-testing of complete blood counts in patients with breast cancer during chemotherapy: A proof-of-concept cohort study in e-oncology

  Lennart Friis-Hansen, Pippi Jonassen Bjørck, Ditte Hartvig, Susanne Andresen, Berit Hulehøj Nielsen, Christina Hansen, Anne Nistrup, Keld Hundewadt, Niels Henrik Holländer

  718-727

• Changes in perfusion and permeability in glioblastoma model induced by the anti-angiogenic agents cediranib and thalidomide

  Jérôme Conq, Nicolas Joudiou, Véronique Préat, Bernard Gallez

  689-700

• Radiation-associated cutaneous mastocytosis: a case report and review of the literature

  Aaron Trando, Karen M. Austin, Brian Hinds, Ah-Reum Jeong, Aaron M. Goodman

  685-688
• 

  18F-FDG-PET/CT in breast cancer imaging: Restaging and Implications for treatment decisions in a clinical practice setting

  Ida Skarping

  669-677

• Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab

  Yana Beulque, Lisa Kinget, Eduard Roussel, Sajedeh Mobaraki, Annouschka Laenen, Philip R. Debruyne, Yannick Van Herck, Marcella Baldewijns, Agnieszka Wozniak, Abhishek D. Garg, Jessica Zucman-Rossi, Gabrielle Couchy, Maarten Albersen, Liesbeth De Wever, Lorenz Haaker, Benoit Beuselinck

  658-668

• Blood biomarkers for neuroaxonal injury and astrocytic activation in chemotherapy-induced peripheral neuropathy

  Jamila Adra, Daniel Giglio, Per Karlsson, Henrik Zetterberg, Zakaria Einbeigi

  636-641

• Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study

  Mirosława Püsküllüoğlu, Aleksandra Konieczna, Katarzyna Świderska, Joanna Streb, Małgorzata Pieniążek, Aleksandra Grela-Wojewoda, Renata Pacholczak-Madej, Anna Mucha-Małecka, Jerzy W. Mituś, Joanna Szpor, Michał Kunkiel, Agnieszka Rudzińska, Michał Jarząb, Marek Ziobro

  620-635

• Real-life experience with sorafenib for advanced and refractory desmoid-type fibromatosis

  Delphine Schampers, Alexander Decruyenaere, Celine Jacobs, Lore Lapeire

  607-611

• The effect of tinzaparin on biomarkers in FIGO stages III-IV ovarian cancer patients undergoing neoadjuvant chemotherapy – the TABANETOC trial: study protocol for a randomized clinical multicenter trial

  Anna Karlsson, Gabriel Lindahl, Anna-Clara Spetz Holm, Karin Bergmark, Pernilla Dahm Kähler, Boglarka Fekete , Ulrika Ottander, Charlotte Öfverman, Pernilla Israelsson, Laila Falknäs, Anders Rosenmüller, Malena Tiefenthal Thrane, Shefqet Halili , Tomas L. Lindahl, Maria C. Jenmalm, Preben Kjølhede

  581-585

• 177Lu-PSMA radioligand therapy for isolated bilateral adrenal metastases from prostate cancer

  Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant, Kornelia Konz, Richard P. Baum

  557-562

• Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up

  Helena Fohlin, Anna Nordenskjöld, Johan Rosell, Mårten Fernö, Tommy Fornander, Lisa Rydén, Lambert Skoog, Bo Nordenskjöld, Olle Stål

  535-541

• Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 – merging clinical research and standard healthcare

  Elisa Bjørgo, Gro L. Fagereng, Hege G. Russnes, Sigbjørn Smeland, Kjetil Taskén, Åslaug Helland

  487-490

• Pioneering the implementation of a precision oncology strategy in Portugal: the Precision Oncology Platform trial

  Beatrice Mainoli, Joana Assis, José Dinis, Rui Henrique, Júlio Oliveira

  482-486

• Comparison of the use of a clinically implemented deep learning segmentation model with the simulated study setting for breast cancer patients receiving radiotherapy

  Nienke Bakx, Maurice van der Sangen, Jacqueline Theuws, Johanna Bluemink, Coen Hurkmans

  477-481

• Robust optimization of the Gross Tumor Volume compared to conventional Planning Target Volume-based planning in photon Stereotactic Body Radiation Therapy of lung tumors

  Thomas L. Fink, Charlotte Kristiansen, Torben S. Hansen, Torben F. Hansen, Rune S. Thing

  448-455

• Clinical trials in older patients with cancer – typical challenges, possible solutions, and a paradigm of study design in breast cancer

  Peeter Karihtala, Aglaia Schiza, Elena Fountzilas, Jürgen Geisler, Icro Meattini, Emanuela Risi, Laura Biganzoli, Antonios Valachis

  441-447

• Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences

  Erika Tóth, Zsófia Kürönya, Edina Soós, Tamás Pintér, Henriett Butz, Zsolt Horváth, Erzsébet Csernák, Vince Kornél Grolmusz, Judit Székely, Tamás Straussz, József Lövey, Levenete Jánvári, László Báthory-Fülöp, Péter Nagy, Csaba Polgár, Attila Patócs

  433-440

• The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST

  Loic Verlingue, Marine Desevre, Marie Polito, Gwenaelle Garin, Christine Rodriguez, Wang Qing, Olivier Tredan, David Perol, Isabelle Ray-Coquard, Sylvie Chabaud, Jean Yves Blay

  411-417

• IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results

  Katarina Puco, Gro Live Fagereng, Sigmund Brabrand, Pitt Niehusmann, Egil Støre Blix, Eli Sihn Samdal Steinskog, Åse Haug, Cecilie Fredvik Torkildsen, Irja Alida Oppedal, Sebastian Meltzer, Åsmund Flobak, Kajsa Anna Margareta Johansson, Line Bjørge, Geir Olav Hjortland, Astrid Dalhaug, Jo-Åsmund Lund, Bjørnar Gilje, Marte Grønlie Cameron, Randi Hovland, Ragnhild S. Falk, Sigbjørn Smeland, Hege Elisabeth Giercksky Russnes, Kjetil Taskén, Åslaug Helland

  379-384

• Desmoplastic non-infantile ganglioglioma mimicking diffuse leptomeningeal glioneuronal tumor: precision diagnostics and therapeutic implications

  Pitt Niehusmann, Henning Leske, Vigdis Nygaard, Hege G. Russnes, Sen Zhao, Anna Latysheva, Ulrikke Straume Wiig, Birute Stankuniene, Aina Ulvmoen

  392-394

• A national precision cancer medicine implementation initiative for Finland

  Katriina J. Jalkanen, Erika Alanne, Sanna Iivanainen, Okko-Sakari Kääriäinen, Minna Tanner, Annika Auranen, Jussi Koivunen, Timo K. Nykopp, Pia Vihinen, Mika Mustonen

  395-397

• PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe

  Kjetil Taskén , Soemeya F. Haj Mohammad, Gro Live Fagereng, Ragnhild Sørum Falk, Åslaug Helland, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Katarina Steen Carlsson, Bettina Ryll, Katriina Jalkanen, Anders Edsjö, Hege G. Russnes, Ulrik Lassen, Ebba Hallersjö Hult, Iwona Lugowska, Jean-Yves Blay, Loic Verlingue, Edvard Abel, Maeve A. Lowery, Matthew G. Krebs, Kristoffer Staal Rohrberg, Kristiina Ojamaa, Julio Oliveira, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom

  385-391

• The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP)

  Soemeya F. Haj Mohammad, Hans J.L. Timmer, Laurien J. Zeverijn, Birgit S. Geurts, Ilse A.C. Spiekman, Karlijn Verkerk, Florentine A.J. Verbeek, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom

  368-372

• Treatment of vulvar cancer recurrence with electrochemotherapy: a case-control study

  Gregor Vivod, Masa Omerzel, Nina Kovacevic, Gorana Gasljevic, Ines Cilensek, Gregor Sersa, Maja Cemazar, Sebastjan Merlo

  351-357
• 

  Implementation of perioperative FLOT compared to ECX/EOX chemotherapy regimens in resectable esophagogastric adenocarcinomas: an analysis of real-world data

  Kristian Egebjerg, Tobias Sørup Andersen, Lene Bæksgaard, Rajendra Garbyal, Mette Siemsen, Michael Achiam, Paul Morten Mau-Sørensen

  322-329

• Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study

  Ivar Hompland, KJetil Boye, Anne Marit Wiedswang, Andri Papakonstantinou, Bård Røsok, Heikki Joensuu, Øyvind Bruland

  288-293

• Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice

  Aino Rajamaki, Marc Sorigue, Roosa E.I. Prusila, Milla E.L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Taina Turpeenniemi-Hujanen, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen

  267-272

• Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice

  Tobias Berg, Maj-Britt Jensen, Maria Rossing, Christian T. Axelsen, Iben Kümler, Lise Søndergaard, Marianne Vogsen, Ann S. Knoop, Bent Ejlertsen

  277-287

• Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)

  Sampsa Kinos, Helga Hagman, Päivi Halonen, Leena-Maija Soveri, Mary O'Reilly, Per Pfeiffer, Jan-Erik Frödin, Halfdan Sorbye, Eetu Heervä, Gabor Liposits, Raija Kallio, Annika Ålgars, Raija Ristamäki, Tapio Salminen, Maarit Bärlund, Carl-Henrik Shah, Ray McDermott, Rebecka Röckert, Petra Flygare, Johannes Kwakman, Arco Teske, Cornelis Punt, Bengt Glimelius, Pia Österlund

  248-258

• Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study

  Rosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, Salvatore Alfieri, Maria Moksnes Bjaanæs, Filippo Pietrantonio, Loris De Cecco, Arsela Prelaj, Claudia Proto, Johan Franzén, Deirdre McDonnell, José Javier Berenguer Pina, Teresa Beninato, Laura Mazzeo, Patrizia Giannatempo, Elena Verzoni, John Crown, Åslaug Helland, Alexander Eustace

  213-219

• Primary splenic angiosarcoma: a case series of a rare oncological entity and diagnostic challenge

  Iris Dirven, Philippe Leclercq, Lionel D'Hondt, Valentine Delmotte, Pierre Lefesvre, Hendrik Reynaert, Frederik Vandenbroucke, Magali Surmont

  192-197

• Is the risk of ischemic heart disease in women after radiotherapy for breast cancer nowadays still (linearly) associated with the mean heart dose?

  Henk Struikmans, Anna Petoukhova, Joop H.M. Schreur, Mirjam E. Mast, Philip M. Poortmans

  175-178

• Area-based disparities in non-small-cell lung cancer survival

  Nelly-Maria Paakkola, Antti Jekunen, Eero Sihvo, Mikael Johansson, Heidi Andersén

  146-153

• Implementing MyChoice® CDx HRD testing for the Nordics: lessons from 2021 to 2023

  Lea Milling Korsholm, Verena Broecker, Mansoor Raza Mirza, Maria Rossing

  70-75

• KIDNEY-PAGER: analysis of circulating tumor DNA as a biomarker in renal cancer – an observational trial. Study protocol

  Laura Iisager, Johanne Ahrenfeldt, Anna Krarup Keller, Tommy Kjærgaard Nielsen, Niels Fristrup, Iben Lyskjær

  51-55

• Carl Blomqvist, Nordic network builder in oncology (1951–2023) †

  Micaela Hernberg, Johanna Mattson, Mikko Tenhunen, Jonas Bergh, Johan Ahlgren, Lars Holmberg, Malin Sund, Mef Nilbert

  3